Search Results for "ustekinumab"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for ustekinumab. Results 11 to 20 of 30 total matches.
See also: Stelara
Bimekizumab (Bimzelx) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
treatment or
phototherapy.
Efficacy: In clinical trials, bimekizumab was more effective
than ustekinumab ...
The FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx (Bimzelx
– UCB) for treatment of moderate to severe plaque
psoriasis in adults who are candidates for systemic
treatment or phototherapy. Bimekizumab is the first
IL-17A/17F antagonist to be approved in the US. It
was approved in the European Union for the same
indication in 2021.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):11-3 doi:10.58347/tml.2024.1694b | Show Introduction Hide Introduction
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
and the IL-12 and -23
inhibitor ustekinumab are alternatives.
In patients with UC that has not responded ...
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and CD
have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12 doi:10.58347/tml.2023.1680a | Show Introduction Hide Introduction
Table: Some Drug Interactions with Drugs for IBD (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
administration of live vaccines
IL-12 and -23 Antagonist –
ustekinumab
flStarting treatment with ustekinumab ...
View the Table: Some Drug Interactions with Drugs for IBD
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e114 doi:10.58347/tml.2023.1680c | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Plaque Psoriasis (online only)
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024 (Issue 1712)
Antagonist
Ustekinumab – Stelara
(Janssen)
45 mg/0.5 mL, 90 mg/mL
prefilled syringes;
45 mg/0.5 mL vials ...
View the Comparison Table: Some Drugs for Plaque Psoriasis
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e160-6 doi:10.58347/tml.2024.1712b | Show Introduction Hide Introduction
Table: Safety of Drugs for IBD in Pregnancy (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
, adalimumab, and golimumab
Ustekinumab No adequate studies in pregnant women; no teratogenic effects reported ...
View the Table: Safety of Drugs for IBD in Pregnancy
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e113 doi:10.58347/tml.2023.1680b | Show Introduction Hide Introduction
Mirikizumab (Omvoh) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
to be approved for this indication.
Ustekinumab (Stelara), an IL-12/23 antagonist, was
approved for treatment ...
The FDA has approved the interleukin (IL)-23
antagonist mirikizumab-mrkz (Omvoh – Lilly) for
treatment of moderately to severely active ulcerative
colitis (UC) in adults. Mirikizumab is the first selective
IL-23 antagonist to be approved for this indication.
Ustekinumab (Stelara), an IL-12/23 antagonist, was
approved for treatment of UC in 2019. The IL-23
antagonist risankizumab (Skyrizi) is approved for
treatment of Crohn's disease.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):46-7 doi:10.58347/tml.2024.1698c | Show Introduction Hide Introduction
Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
.
The IL-12/23 antagonist ustekinumab (Stelara)2 or the
integrin receptor antagonist vedolizumab (Entyvio ...
The injectable interleukin (IL)-23 antagonist
risankizumab-rzaa (Skyrizi – Abbvie) has been
approved by the FDA for treatment of moderately
to severely active Crohn's disease (CD) in adults.
Risankizumab was approved earlier for treatment of
plaque psoriasis and psoriatic arthritis.
Drugs for Psoriatic Arthritis
The Medical Letter on Drugs and Therapeutics • Dec 30, 2019 (Issue 1588)
TNF inhibitor may
respond to another.
▶ The IL-12 and -23 inhibitor ustekinumab (Stelara) or the IL ...
Psoriatic arthritis is a chronic inflammatory
arthropathy associated with psoriasis. A recent review
found that about 20% of patients with psoriasis have
psoriatic arthritis. Updated guidelines for treatment
of psoriatic arthritis have recently been published.
Apremilast (Otezla) for Psoriatic Arthritis
The Medical Letter on Drugs and Therapeutics • May 26, 2014 (Issue 1443)
added or substituted.2 Ustekinumab
(Stelara), a human interleukin-12 and -23 antagonist,
has also ...
Apremilast (Otezla – Celgene), an oral phosphodiesterase
type-4 (PDE4) inhibitor, has been approved
by the FDA for treatment of active psoriatic arthritis in
adults. It is the fi rst PDE4 inhibitor to be approved for this
indication.
Secukinumab (Cosentyx) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015 (Issue 1465)
, and infliximab) and ustekinumab,
a human IL-12 and -23 antagonist.2
MECHANISM OF ACTION — IL-17A is a naturally ...
Secukinumab (Cosentyx – Novartis), an injectable
human interleukin (IL)-17A antagonist, has been
approved by the FDA for treatment of moderate to
severe plaque psoriasis in adult patients who are
candidates for systemic therapy or phototherapy.
It is the first IL-17 inhibitor to be approved for any
indication in the US.